Drug Profile
Amilomotide
Alternative Names: Alzheimer's disease virus-like particle-based vaccine - Novartis; Alzheimer's disease VLP-based vaccine - Novartis; Beta-amyloid protein immunotherapy - Novartis; CAD 106; Immunodrug™ for Alzheimer's disease - NovartisLatest Information Update: 20 Sep 2021
Price :
$50
*
At a glance
- Originator Cytos Biotechnology
- Developer Cytos Biotechnology; Novartis
- Class Alzheimer vaccines; Antidementias; Neuroprotectants; Virus-like particle vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Alzheimer's disease
- Discontinued Hypersensitivity; Rheumatoid arthritis
Most Recent Events
- 26 Jul 2021 Adverse events and efficacy data from a phase II/III trial in Alzheimer's disease presented at the Alzheimer's Association of International Conference (AAIC-2021)
- 08 Jan 2020 Discontinued - Phase-II for Alzheimer's disease in Switzerland, Norway, Sweden, Spain, Netherlands, Italy, Germany, Canada (IM)
- 15 Jul 2019 Discontinued - Phase-II/III for Alzheimer's disease in USA, Finland, Belgium, United Kingdom, Finland (IM)